Financial News
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
June 07, 2024 at 18:20 PM EDT
The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
